<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"
        xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1"
        xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd http://www.google.com/schemas/sitemap-news/0.9 http://www.google.com/schemas/sitemap-news/0.9/sitemap-news.xsd http://www.google.com/schemas/sitemap-image/1.1 https://www.google.com/schemas/sitemap-image/1.1/sitemap-image.xsd">
    <url>
      <loc>https://www.israelhealthcarenews.com/article/908732959-silexion-therapeutics-announces-successful-submission-of-phase-2-3-clinical-trial-application-to-germany-s-bfarm-for-sil204-in-kras-driven-locally</loc>
      <news:news>
        <news:publication>
          <news:name>Israel Healthcare News</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-28T12:45:00+00:00</news:publication_date>
        <news:title>Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml-eu.globenewswire.com/media/1070dc42-db79-4712-af48-38ffbdf3b140/small/screenshot-2025-05-13-at-15-29-06-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.israelhealthcarenews.com/article/908733220-polypid-to-present-data-from-shield-ii-phase-3-trial-demonstrating-reduced-severity-of-surgical-site-infection-at-surgical-infection-society-2026</loc>
      <news:news>
        <news:publication>
          <news:name>Israel Healthcare News</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-28T12:30:00+00:00</news:publication_date>
        <news:title>PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/43a11cdb-f86b-4d84-bfb0-1870a0a2cb4e/medium/graph-showing-number-of-patients-with-asepsis-score-20-itt-c.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.israelhealthcarenews.com/article/908733751-enlivex-treasury-update-total-rain-holdings-rise-to-78-819-756-062-tokens-as-of-april-27-2026-representing-an-aggregated-value-of-567-million</loc>
      <news:news>
        <news:publication>
          <news:name>Israel Healthcare News</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-28T12:30:00+00:00</news:publication_date>
        <news:title>Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/27d4e006-8709-4fd1-8341-5b58381487d4/small/picture1-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.israelhealthcarenews.com/article/908725714-prf-technologies-announces-fda-clearance-of-ind-application-for-ocuring-k-phase-ii-clinical-trial</loc>
      <news:news>
        <news:publication>
          <news:name>Israel Healthcare News</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-28T12:00:00+00:00</news:publication_date>
        <news:title>PRF Technologies Announces FDA Clearance of IND Application for OcuRing™-K Phase II Clinical Trial</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/245f4060-af56-451d-a821-f5ee6fb5d2e5/small/picture1-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.israelhealthcarenews.com/article/908535169-inspiremd-to-announce-first-quarter-2026-financial-results</loc>
      <news:news>
        <news:publication>
          <news:name>Israel Healthcare News</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-27T20:05:00+00:00</news:publication_date>
        <news:title>InspireMD to Announce First Quarter 2026 Financial Results</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml-eu.globenewswire.com/media/5aefda10-5578-41c7-a1c0-9c4b700687c0/small/inspiremd-jpg.jpg</image:loc>
        </image:image>
    </url>
</urlset>
